SHINE Medical Technologies recently announced its 2019 year-end report, which included updates on its construction progress, continued investor support, its new therapeutics division and information about commercial and regulatory news.

“2019 was SHINE’s most productive, successful year yet, driven by an incredibly dedicated team that moved the company forward in important ways,” SHINE CEO Greg Piefer said in a statement. “Our team’s progress on the construction of our production facility is the strongest signal to date that SHINE will play a big role in solving the global shortage of molybdenum-99.”

According to the report, SHINE broke ground for its medical isotope production facility in May with production set to begin in 2022. The Janesville, Wis., company raised $125 million, including $50 million from leading global investment firm Oaktree Capital Management and $15 million from the federal government.

In addition, SHINE created a therapeutics division focused on fundamental change to cancer treatment, filed an application with the U.S. Nuclear Regulatory Commission to produce medical isotopes at its facility, and added former House of Speaker Paul Ryan to its board of directors.